Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clinuvel Pharmaceuticals ADR CLVLY

Healthcare Biotechnology
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial... see more

Recent & Breaking News (OTCPK:CLVLY)

    CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP

    GlobeNewswire 8 hours ago

    Afamelanotide in fair-skinned Parkinson's patients

    GlobeNewswire June 17, 2024

    Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

    GlobeNewswire March 28, 2024

    Malibu shines a light on CLINUVEL's pioneering work in photomedicine

    GlobeNewswire March 4, 2024

    CLINUVEL Launches CYACÊLLE, Next Generation Solar Care

    GlobeNewswire February 28, 2023

    Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

    GlobeNewswire February 23, 2023

    CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

    GlobeNewswire February 1, 2023

    CLINUVEL Trial Results Show Drug Reduces DNA Damage

    GlobeNewswire January 15, 2023

    CLINUVEL progresses vitiligo treatment program

    GlobeNewswire May 9, 2022

    Positive final results in stroke

    GlobeNewswire May 3, 2022

    Letter to shareholders from CLINUVEL's CEO

    GlobeNewswire April 29, 2022

    CLINUVEL Expands Pharmaceutical Portfolio

    GlobeNewswire November 7, 2021